Gardisil-9
PreclinicalBiologic
Gardisil-9 is one of 48 biologic programs targeting Cervical Cancer. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
115 competitors in Cervical Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Avastin
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Keytruda
Merck & Co.Phase 3
Trodelvy
GileadPhase 3
Lenvima
EisaiPhase 3
Taxotere
AAvyxa
Phase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 3
Rescue
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gardisil-9. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IIndiana University